google-site-verification: google28f501b00d980d5f.html Boehringer Ingelheim and Global Stem Cell Technology to bring ground-breaking innovation to equine market - Vetpol Community

Announcement

Collapse
No announcement yet.

Boehringer Ingelheim and Global Stem Cell Technology to bring ground-breaking innovation to equine market

Collapse
X
Collapse

  • Boehringer Ingelheim and Global Stem Cell Technology to bring ground-breaking innovation to equine market

    Click image for larger version

Name:	Boehringer.jpg
Views:	29
Size:	35.4 KB
ID:	48169
    The Boehringer Ingelheim Animal Health Business Unit and Global Stem Cell Technology (GST) entered into a partnership to enable European veterinarians and horse owners to benefit from ground-breaking innovation. Following marketing authorisation, Boehringer Ingelheim will exclusively distribute this highly innovative product in the EU. The product has been developed by GST and is the first-ever stem cell product in the veterinary world1 which was recommended marketing authorisation by the European Medicines Agency (EMA)1 earlier this year.

    Based on horse-blood-derived stem cells, which are specially primed, this medication is a candidate of the so-called novel therapies.

    Lameness is a common disease in horses and impacts their performance as well as welfare. Current treatment is not satisfactory for all cases and there is a clear need for innovation and new treatment options. Hence, the significant interest in treatment beyond symptoms, namely combatting the underlying root cause.

    “Priming the cells towards cartilage aids them to deliver the right activities in the affected joint,” shares Jan Spaas PhD, Veterinarian and CEO of GST. “We are absolutely delighted with this partnership as well as EMA´s positive opinion - the potential for the treatment is vast, since a quarter of the entire equine population develops osteoarthritis at some point in their life.”

    “Boehringer Ingelheim is dedicated to providing new and innovative products, whether through our own R&D activities or by working in partnership with true experts in the field,” says Dr. Erich Schoett, Head of Strategic Business Unit Equine at Boehringer Ingelheim. “GST impressed us with a wealth of expertise in the area of regenerative medicine and we do see an immense synergy in the close collaboration we are having. It is a real privilege to launch an industry first of this magnitude and we are working together closely to bringing this product to market.”

    1Press release issued by the European Medicines Agency on 22 June 2018: https://www.ema.europa.eu/en/news/fi...-authorisation
    Brought to you by Boehringer Ingelheim Animal Health UK Ltd.

    Further information available from Boehringer Ingelheim Animal Health UK Ltd., RG12 8YS, UK. UK Tel: 01344 746960 (sales) or 01344 746957 (technical), IE Tel: 01 291 3985 (all queries). Email:vetenquiries@boehringer-ingelheim.com. ©2019 Boehringer Ingelheim Animal Health UK Ltd. All rights reserved. Date of preparation: Dec 2018 AHD11801. Use Medicines Responsibly.

    Boehringer Ingelheim
    Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.
    Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales.
    As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success, rather than short-term profit. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.
    More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com.

    Boehringer Ingelheim Animal Health Business Unit
    Boehringer Ingelheim is the second largest animal health business in the world. We are committed to creating animal wellbeing through our large portfolio of advanced, preventive healthcare products and services. With net sales of 3.9 billion euros (2017) and around 10,000 employees worldwide, we are present in more than 150 markets. For more information click here.

    Global Stem cell Technology NV
    GST is a privately owned company supported by Anacura and PMV. The main activities of GST are research and development and production of veterinary stem cell based products and their biotechnological applications. As a basis for stem cell therapies, GST uses highly potent stem cells from blood of mammals. GST thus translates regenerative medicine into clinical applications. The company was founded by veterinary stem cell researcher Jan H. Spaas (CEO) who is inventor of six patents and leading author on more than 25 scientifically peer-reviewed publications in this field. GST is globally ranked within the top 10 start-ups in animal health2. For more information, visit www.gst.be.

    2https://pages.agribusinessintelligence.informa.com/animal-pharm-disruptors-innovators-2018


      Posting comments is disabled.

    Categories

    Collapse

    Article Tags

    Collapse

    Latest Articles

    Collapse

    • Zoetis UK Ltd – We Have Moved
      by Kristina Kisbee

      Zoetis Ltd would like to let those of you who may not know we have moved to a new office location. As of the 17th June our new home is;

      Zoetis UK Ltd, First Floor, Birchwood Building, Springfield Drive, Leatherhead, Surrey, KT22 7LP


      It is an exciting move which sees us set up in a brand-new office space. A new space that is much appreciated as we continue to grow our teams to support our evolving range of products and solutions we offer across the continuum of care....
      Today, 01:02 PM
    • Davies Green Team takes action for World Environment Day
      by Kristina Kisbee


      The enthusiastic Green Group at Davies Veterinary Specialists (Davies), Hertfordshire got stuck in to World Environment Day last week, as part of their continual commitment to sustainability in practice. As well as encouraging staff to make pledges, calculate their own carbon footprints, and pedal to make smoothies, they unveiled a pet owner newsletter to make suggestions on green pet ownership and offered reusable water bottles to clients seen at Davies on June 5th.

      World
      ...
      Today, 09:24 AM
    • Purina reveals a revolutionary approach to managing cat allergens
      by Kristina Kisbee


      For the first time in history, Purina scientists demonstrate a proactive way to significantly reduce the active levels of the major cat allergen, Fel d1, at its source in cats’ saliva. As many as one in five adults worldwide are sensitised to cat allergens.

      Avoiding cats is a cornerstone of managing allergens, an approach that may leave cats looking for a new home. Taking advantage of natural allergen-antibody interactions, Purina researchers discovered how to safely
      ...
      Today, 09:20 AM
    • Vets urged to THINK TWICE this Dry Eye Awareness Month
      by Kristina Kisbee


      Ocular conditions account for around one in ten canine consultations in first opinion practices1 and in the lead up to Dry Eye Awareness Month, Bayer are asking vets to think twice about their approach to Dry Eye management.

      In the case of KCS, early diagnosis and treatment can have a significant impact on prognosis, but unfortunately, 46% of dog owners are not aware of the risks.2 Some KCS cases may present with quite mild clinical signs, particularly in the early stages
      ...
      14-06-2019, 07:07 AM
    • Record-breaking VET Festival Champions Wellness
      by Kristina Kisbee


      Notching up record delegate and exhibitor numbers for 2019, this year’s VET Festival, received an overwhelmingly positive response from delegates for the calibre of speakers and entertainment. The event took place at Loseley Park, Guildford on 7-8 June.

      With wellness a strong focus for VET Festival, the Wellness lecture tent was packed for Lara Heimann, an American who has achieved global recognition for her unique vinyasa yoga style and regularly leads international
      ...
      14-06-2019, 07:06 AM
    • Vetsure launch new Large Animal and Equine Buysure Platinum buying group services
      by Kristina Kisbee


      Since their inception 10 years ago, Vetsure have been offering market-leading purchase savings to all practice types through their Buysure for Vets and Buysure Platinum buying groups. Until recently, however, their Platinum offering – whereby members benefit from corporate terms in return for use of preferred products – has been limited to small animal practices. That has all changed now with the launch of the LA/Equine Buysure Platinum Group.

      “There is considerable disruption
      ...
      13-06-2019, 11:51 AM
    Working...
    X